EHA 2018 | Outcomes by prior lines of therapy from the ZUMA-1 trial

On Saturday 16^th June an oral abstract session took place at the 23^rd congress of the European Hematology Association (EHA). Abstract S801 was presented by Olalekan Oluwole, Vanderbilt-Ingram Cancer Center, Nashville, US on the outcomes by prior lines of therapy from the ZUMA-1 trial. The ZUMA-1 trial investigated axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B-cell lymphoma.

The safety and efficacy outcomes were assessed by the number of prior lines of therapy 1-2 (n = 32), 3 (n = 33), 4 (n = 30) or ≥5 (n = 13). The objective response rate (ORR) for partial and complete responses, for 1-2 prior lines of therapy was 91%, for 3 prior lines of therapy it was 94%, for 4 prior lines of therapy was 80% and ≥5 lines of therapy was 38%.

The adverse events (AEs) by prior line of therapy included:

• 1-2 prior lines, related AEs = 34%, cytokine release syndrome (CRS) = 16% and neurologic events = 28%
• 3 prior lines related AEs = 27%, CRS = 9% and neurologic events = 33%
• 4 prior lines related AEs = 23%, CRS = 10% and neurologic events = 20%
• ≥5 prior lines related AEs = 54%, CRS = 15% and neurologic events = 54%

The results from this study demonstrated long-term clinical benefit for patients with refractory large B-cell lymphoma regardless of prior lines of therapy.